Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Early changes of beta-Catenins and Menins in spinal cord dorsal horn after peripheral nerve injury.

Authors: Zhang, X  Chen, G  Xue, Q  Yu, B 
Citation: Zhang X, etal., Cell Mol Neurobiol. 2010 Aug;30(6):885-90. doi: 10.1007/s10571-010-9517-9. Epub 2010 Apr 6.
Pubmed: (View Article at PubMed) PMID:20369282
DOI: Full-text: DOI:10.1007/s10571-010-9517-9

Injury to the peripheral nervous system can lead to spontaneous pain, hyperalgesia and allodynia. Previous studies have shown sprouting of Abeta-fibres into lamina II of the spinal cord dorsal horn after nerve injury and the formation of new synapses by these sprouts. beta-Catenin and menin as synaptogenic factors are critically involved in synapse formation. However, the roles of beta-catenin and menin in neuropathic pain are still unclear. Using Western blot analysis we investigated the changes of beta-catenin and menin in the spinal dorsal horn after unilateral spared nerve injury (SNI). We demonstrated an increase in both beta-catenin and menin protein levels in the ipsilateral spinal dorsal horn at days 1 and 3 following spared nerve injury (P < 0.05). These increases were associated with changes in paw withdrawal threshold to mechanical stimuli and weight bearing deficit suggestive of pain behavior and spontaneous ongoing pain respectively. However, the injury-associated increases in beta-catenins and menins levels returned to control levels at day 14. In conclusion, these results indicate that peripheral nerve injury induces upregulation of beta-catenins and menins in the dorsal horn of the spinal cord, which may contribute to the development of chronic neuropathic pain. Antagonists of these molecules may serve as new therapeutic agents.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 9589142
Created: 2014-11-10
Species: All species
Last Modified: 2014-11-10
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.